QC
CNTX icon

Quadrature Capital’s Context Therapeutics CNTX Stock Holding History

Quadrature Capital’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,220
Closed -$67.9K – 1450
2025
Q4 		$67.9K Buy
+46,220
New +$54K ﹤0.01% 1144
2022
Q4 		– Sell
-45,889
Closed -$51K – 887
2022
Q3 		$51K Buy
+45,889
New +$82.6K ﹤0.01% 809

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Quadrature Capital's CNTX Position: Q1 2026 in Review

Quadrature Capital sold out of Context Therapeutics (CNTX) in Q1 2026, closing a stake of 46,220 shares — an estimated $67.9K sold.

Quadrature Capital first reported a position in CNTX in Q3 2022 and held it in 2 quarters. The position peaked at $67.9K in Q4 2025. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Quadrature Capital reported no remaining Context Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 46,220 Context Therapeutics shares in Q1 2026, an estimated $67.9K.
  • Quadrature Capital first reported a position in Context Therapeutics in Q3 2022 and held it in 2 quarters.
  • Quadrature Capital's Context Therapeutics position peaked at $67.9K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.